Quality & complianceOfficial

Denmark flags supply problems for Krka's Nimvastid rivastigmine capsules until mid-December

🇩🇰 DKMA · Mon 02 Nov 2026

The Danish Medicines Agency says production problems at Krka Sverige AB are disrupting supply of Nimvastid 1.5 mg hard capsules, with disruption expected from late April to mid-December 2026.

The Danish Medicines Agency (DKMA) has published a supply notice for Nimvastid 1.5 mg hard capsules, marketed in Denmark by Krka Sverige AB. The agency says there are current problems with the product's supply.

The notice was first published on 1 May 2026 and updated on 2 November 2026. It identifies the active substance as rivastigmine (as rivastigmine hydrogen tartrate), with the ATC code N06DA03.

DKMA gives the expected period of disruption as end of April to mid-December 2026. It states the cause as production problems. The notice does not say how many batches or pack sizes are affected, nor does it describe any mitigation measures.

The agency directs questions about the current status to the company. The notice also points readers to DKMA's wider page of supply notices for medicines.

What it means for your team

  • Supply planners should note the stated disruption window, end of April to mid-December 2026, and plan for it to run beyond the 2 November update.
  • The notice names production problems as the cause but gives no volumes or pack-level detail, so teams will need to ask Krka Sverige AB directly for current status.
  • Market-access and pharmacy-facing teams may want to review alternative sourcing for rivastigmine 1.5 mg capsules; the notice itself describes no alternatives.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →